J&J to repurchase $5 billion in shares; NICE approves wider statin use;

@FiercePharma: Top-read on FP Monday: Gilead litigation says claims by Merck, AbbVie on Sovaldi are patently wrong. Article | Follow @FiercePharma

@TracyStaton: ICYMI: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. Story | Follow @TracyStaton

@EricPFierce: French animal health drugmaker Virbac sees US sales hurt by last year's recall of Iverhart Plus. More from FierceAnimalHealth | Follow @EricPFierce

@CarlyHFierce: Defensive Allergan plots 1,500 job cuts, hikes forecast to fight off Valeant. Report | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) has announced a $5 billion share repurchase program. Release

> U.K. cost watchdog NICE has approved wider statin use, but critics warn that it could "distort" care. More

> GlaxoSmithKline ($GSK) says a ViiV Healthcare study of a combined maraviroc treatment showed inferior efficacy compared with an alternative combination. Report

> Lundbeck has launched alcohol dependence med Selincro in Spain. Release

> Arena Pharma ($ARNA) and Teva ($TEVA) have inked a marketing and supply deal for obesity drug Belviq in Israel. More

> Stallergenes has acquired Argentina's Alergo Pharma. Release

Medical Device News

@FierceMedDev: Profit stumble pushes Philips to focus on healthcare. Article | Follow @FierceMedDev

@StacyALawrence: Miss Idaho wears insulin pump in swimsuit competition. Item | Follow @StacyALawrence

@VarunSaxena2: ICYMI yesterday: FDA approves expandable implant for spinal fusion surgery. News | Follow @VarunSaxena2

@MichaelGFierce: RT @EmilyMFierce: Which 15 disease areas get the most funding from NIH? Report | Follow @MichaelGFierce

@EmilyWFierce: Auditory brainstem implant provides alternative to cochlear device, offers profoundly deaf children a chance to hear. More from the Los Angeles Times | Follow @EmilyWFierce

> Intersect, Ocular ready to test the med tech IPO waters. Article

> Smart bandage advances patient monitoring technology. More

> Spinal fusion implants enter market amid growing skepticism from insurers. Article

Biotech News

@FierceBiotech: $ZIOP, $XON tackle CAR-T in expanded partnership. More | Follow @FierceBiotech

@JohnCFierce: Biosimilars set to boom as new patent cliff on biologic superstars looms. Article | Follow @JohnCFierce

@DamianFierce: "It's like surfing. If you aren't in the water you'll never catch that monster wave." -- CEO on going public. More | Follow @DamianFierce

@EmilyMFierce: You know you're reading a press release from the U.K. when it has the word "whilst" in it. | Follow @EmilyMFierce

> AstraZeneca adds Advaxis to a growing roster of immuno-oncology partners. Story

> With a $650M gift and a trove of genomic data, Broad sets out to innovate in schizophrenia. Article

> Sage takes to the FDA fast track with its lead rare disease drug. News

> Atlas, NEA bankroll a $30M round for synthetic biology upstart Synlogic. Report

Biotech Research News

> Top 15 NIH-funded disease areas. Report

> Simulated human heart aims to screen drugs for adverse effects. More

> First U.S.-acquired chikungunya case detected. Item

> Simulated human heart aims to screen drugs for adverse effects. Article

> Enzyme may provide new target for Alzheimer's disease. Story

Pharma Manufacturing News

> FedEx to fight charges it was key link in supply chain for illegal drugs. News

> FDA again warns that Texas compounder's products may not be sterile. Item

> GSK, J&J push for genetic engineering of opium. More

> American Health recalls epilepsy drug and ibuprofen over possible tablet switch. Story

> Lilly to cut 100 production jobs in Indianapolis, but workers get shot at others. Article

And Finally... Missouri is the only state in America that has declined to keep a prescription drug database. More (sub. req.)

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.